Investigar

Do People Who Exercise More Have a Lower Risk of ALS?

junio 26, 2024 Comentarios desactivados en Do People Who Exercise More Have a Lower Risk of ALS?

MINNEAPOLIS – Moderate levels of physical activity and fitness may be linked to a reduced risk of amyotrophic lateral sclerosis (ALS) later in life, according to a new study published…

Studio City Life Magazine: Charity Spotlight

mayo 1, 2024 Comentarios desactivados en Studio City Life Magazine: Charity Spotlight

The May 2024 issue of Studio City Life Magazine featured ALS Network president and CEO Sheri Strahl, along with ALS Network Advisory Trustee Dr. Richard Smith. Readers received details on…

Celebrating Collaboration: the 2024 Death Valley Ride to Cure ALS

abril 24, 2024 Comentarios desactivados en Celebrating Collaboration: the 2024 Death Valley Ride to Cure ALS

On April 9, Jaime Lafita, a native of Bilbao, Spain, who has been living with amyotrophic lateral sclerosis (ALS) since 2016, started his journey of the Death Valley Ride to…

Celebrating the 2024 Sheila Essey Award Winner

abril 15, 2024 Comentarios desactivados en Celebrating the 2024 Sheila Essey Award Winner

Eva Feldman, M.D., Ph.D., FAAN, has been named the 2024 recipient of the Sheila Essey Award for ALS Research. Dr. Feldman has dedicated her career to studying neurodegenerative diseases and…

New ALS Research and Moonshot Era

abril 4, 2024 Comentarios desactivados en New ALS Research and Moonshot Era

A trailblazer in the field of ALS research and therapy development, Richard Smith, MD, director of the Center for Neurologic Study, and a member of the ALS Network’s scientific review…

Mechanisms of ALS Medications

marzo 29, 2024 Comentarios desactivados en Mechanisms of ALS Medications

In January 2024, Jill Ann Goslinga, MD, MPH, Assistant Professor, UCSF Department of Neurology, gave a special presentation about the mechanisms of ALS medications at the ALS Network’s (formerly the…

BrainStorm Cell Therapeutics

Phase 3b Trial Design Unveiled at Clinical/Scientific Conference

febrero 27, 2024 Comentarios desactivados en Phase 3b Trial Design Unveiled at Clinical/Scientific Conference

Planned Phase 3b trial Designed to Confirm Efficacy and Safety of NurOwn in mild-to-moderate ALS patients NEW YORK, Feb. 27, 2024 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer…

2024 Barber ALS Research Award Winners

enero 30, 2024 Comentarios desactivados en 2024 Barber ALS Research Award Winners

Notable ALS advocate Jim Barber was an instrumental voice in the ALS community who advocated for ALS research. A major outcome of his work was the formation of the California…

Highlights of the 14th Annual California ALS Research Summit

enero 30, 2024 Comentarios desactivados en Highlights of the 14th Annual California ALS Research Summit

The 14th annual California ALS Research Summit was a seminal event in the world of ALS research and care, with over 200 researchers, investigators, clinicians, biotech companies, partner organizations, and…

BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics anuncia el resultado de la reunión de la FDA sobre NurOwn® en la ELA

diciembre 7, 2023 Comentarios desactivados en BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS

NUEVA YORK, 7 de diciembre de 2023 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), un desarrollador líder de terapias con células madre adultas para enfermedades neurodegenerativas, anunció hoy la finalización de un productivo…